The recent COVID-19 carries potential risk factors for VTE and worse clinical course in some patients has an association with thrombosis. While low molecular weight heparins are under investigation for appropriate dosage, other elements could be useful. We share our experience about two patients with unexpected clinical course
Early antithrombotic therapy and COVID-19:a better clinical course? New evidences from real-life cases
Salvatore Signorelli;
2020-01-01
Abstract
The recent COVID-19 carries potential risk factors for VTE and worse clinical course in some patients has an association with thrombosis. While low molecular weight heparins are under investigation for appropriate dosage, other elements could be useful. We share our experience about two patients with unexpected clinical courseFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
corvasa_cor-202088-0009 (00000002).pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
427.93 kB
Formato
Adobe PDF
|
427.93 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
